2025 / 05

Next Paper
DOI: 10.24075/brsmu.2025.051
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

OPINION

Prospects of finding pathologically based therapies for epilepsy associated with brain glioma

Ashkhatsava TI1, Kalinin VA2, Yakunina AV2, Poverennova IE2
About authors

1 Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency, Moscow, Russia

2 Samara State Medical University, Samara, Russia

Correspondence should be addressed: Vladimir A. Kalinin
Chapaevskaya, 89, Samara, 89443099, Russia; ur.umsmas@ninilak.a.v

About paper

Author contribution: Ashkhatsava TI — data collection and systematization; Kalinin VA, Yakunina AV — data analysis, manuscript writing; Poverennova IE — manuscript editing.

Received: 2025-09-18 Accepted: 2025-10-06 Published online: 2025-10-27
|
  1. Luyken C, Blümcke I, Fimmers R, Urbach H, Elger C, Wiestler O, et al. 2003. The spectrum of longterm epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia. 2003; 44: 822–30.
  2. Lange F, Hornschemeyer J, Kirschstein T.Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Cells. 2021; 10 (5): 1226. Available from: https://doi.org/10.3390/cells10051226.
  3. Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019; 573 (7775): 532‒38. Available from: https://doi.org/10.1038/s41586-019-1564-x.
  4. Yuen TI, Morokoff AP, Bjorksten A, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012; 79 (9): 883‒9. Available from: https://doi.org/10.1212/WNL.0b013e318266fa89.
  5. Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008; 215 (3): 593‒602. Available from: https://doi.org/10.1002/jcp.21366.
  6. Yi L, Fan X, Li J, et al. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Aging (Albany NY). 2021; 13 (3): 3645‒60. Available from: https://doi.org/10.18632/aging.202328.
  7. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010; 62 (3): 405‒96. Available from: https://doi.org/10.1124/pr.109.002451.
  8. Timechko EE, Lysova KD, Yakimov AM, Paramonova AI, Vasilieva AA, Kantimirova EA, et al. Circulating microRNAs as Biomarkers of Various Forms of Epilepsy. Med Sci. 2025; 13: 7. Available from: https://doi.org/10.3390/medsci13010007.
  9. Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. Epilepsy Behav. 2020; 104: 106876. Available from: https://doi.org/10.1016/j.yebeh.2019.106876.
  10. Rosche J, Piek J, Hildebrandt G, Grossmann A, Kirschstein T, Benecke R. Perampanel in der Behandlung eines Patienten mit Glioblastoma multiforme ohne IHD-1-Mutation und ohne MGMT-Promotor-Methylierung. Fortschr Neurol Psychiatr. 2015; 83 (5): 286‒9. Available from: https://doi.org/10.1055/s-0034-1399459.
  11. Roh TH, Moon JH, Park HH, et al. Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. Sci Rep. 2020; 10 (1): 10783. Available from: https://doi.org/10.1038/s41598-020-67697-w.
  12. Fukuyama K, Ueda Y, Okada M. Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels. Pharmaceuticals (Basel). 2020; 13 (6): 117. Available from: https://doi.org/10.3390/ph13060117.
  13. Bianconi A, Koumantakis E, Gatto A, Zeppa P, Saaid A, Nico E, et al. Effects of Levetiracetam and Lacosamide on survival and seizure control in IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy. Brain and Spine. 2024; 4: 102732. Available from: https://doi.org/10.1016/j.bas.2023.102732.
  14. Vasilenko AV, Ulitin AYu, Ablaev NR, Dikonenko MV, Mansurov AS, SHajhov M. M. Epilepsiya u bol'nyh s gliomami: mekhanizmy, lechenie i vliyanie protivosudorozhnoj terapii. Rossijskij zhurnal personalizirovannoj mediciny. 2023; 3 (3): 38‒47. DOI: 10.18705/2782-3806-2023-3-3-38-47. Russian.
  15. Kopachev DN, SHishkina LV, SHkatova AM, Golovteev AL, Troickij AA, Grinenko OA, i dr. Glionejronal'nye opuholi, associirovannye s epilepsiej. ZHurnal nevrologii i psihiatrii im. S. S. Korsakova. 2022; 122 (4): 127–34. Dostupno po ssylke: https://doi.org/10.17116/jnevro2022122041127. Russian.
  16. Lebedeva AV, Burd SG, Vlasov PN, Ermolenko NA, ZHidkova IA, Zyryanov SK, i dr. Lechenie epilepsii, associirovannoj s pervichnymi i metastaticheskimi opuholyami golovnogo mozga. Epilepsiya i paroksizmal'nye sostoyaniya. 2021; 13 (3): 286‒304. Dostupno po ssylke: https://doi.org/10.17749/2077-8333/epi.par.con.2021.099. Russian.